In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

CASI Pharmaceuticals, Inc.. Trade Record

NASDAQ:CASI CASI Pharmaceuticals, Inc. stock gains 15.07% Exit Jul 10, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CASI Jun 22, 2018, priceSeries
About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company's late-stage clinical drug candidates include , such as MARQIBO, a microtubule inhibitor for the treatment of adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular b-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Trade Information
Trade Type
LONG
ReliabilityScore™
94.59
Entry Date
Jun 22, 2018
Entry Price
6.28
Sell Date
Jul 10, 2018
Sell Price
7.23
Net Gain
15.07%
Hold Time
11 Trading Days